March 4, 2020 at 18:40 JST
Takeda Pharmaceutical Co. said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.
The Japanese drug maker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.
Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.
“We will do all that we can to address the novel coronavirus threat ... (and) are hopeful that we can expand the treatment options,” Rajeev Venkayya, president of Takeda’s vaccine business, said in the statement.
Takeda said it was in talks with various health and regulatory agencies and health-care partners in the United States, Asia and Europe to move forward its research into the drug.
Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.
The Asahi Shimbun aims “to achieve gender equality and empower all women and girls” through its Gender Equality Declaration.
Let’s explore the Japanese capital from the viewpoint of wheelchair users and people with disabilities with Barry Joshua Grisdale.
This special page portrays the dramatic arrest of Carlos Ghosn and the twists and turns that followed.
This special page reviews what the former Nissan Motor Co. chairman left during his 19 years in Japan.
Baseball star Ichiro Suzuki had much to say on March 21, 2019, the day he hung up his spikes.
This special page details how journalists uncovered shady transactions through Bermuda and other tax havens.